Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: A matter of the receptors?

BJU International

Volumn 111, Issue 7, 2013, Pages 1021-1030

  Tolkach, Yuri ^a   Joniau, Steven ^b   Van Poppel, Hendrik ^b  

^a S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

androgen deprivation therapy; GnRH antagonist; LHRH agonist; LHRH receptor; prostate cancer

Indexed keywords

BUSERELIN; DEGARELIX; FOLLITROPIN; FOLLITROPIN RECEPTOR; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; LEUPRORELIN; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVANCED CANCER; CANCER GRADING; CANCER GROWTH; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; DOWN REGULATION; DRUG TARGETING; HORMONE SYNTHESIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, HORMONAL; FOLLICLE STIMULATING HORMONE; HUMANS; MALE; PITUITARY GLAND; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; SIGNAL TRANSDUCTION; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84877698649     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2013.11796.x     Document Type: Review

References (73)

1. Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. 2012. Available at: http://www.uroweb.org/gls/pdf/ 08%20Prostate%20Cancer-LR%20March%2013th%2012.pdf. Accessed 12 June 2012
2. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-1538
3. Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol 2011; 186: 889-897
4. McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelixversusleuprolide acetate in men with prostate cancer. Urology 2001; 58: 756-761
5. Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001; 165: 1585-1589
6. Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a Phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010; 57: 836-842
7. Tieva A, Bergh A, Damber JE,. The clinical implications of the difference between castration, gonadotrophin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate. BJU Int 2003; 91: 227-233
8. Harrison GS, Wierman ME, Nett TM, Glode LM,. Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr Relat Cancer 2004; 11: 725-748
9. Tieva A, Stattin P, Wikström P, Bergh A, Damber JE,. Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate 2001; 47: 276-284
10. Tieva A, Wilkström P, Olofsson JI, Bergh A, Damber JE,. Expression of gonadotropin-releasing hormone receptor mRNA in the rat ventral prostate and dunning R3327 PAP adenocarcinoma before and after castration. Prostate 1999; 39: 101-107
11. Fekete M, Redding TW, Comaru-Schally AM, et al. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate 1989; 14: 191-208
12. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG,. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000; 163: 623-629
13. Straub B, Müller M, Krause H, Schrader M, Miller K,. Real-time quantitative reverse transcriptase-polymerase chain reaction for luteinizing hormone-releasing hormone receptor gene mRNA expression in human prostate cancer. Urology 2003; 62: 172-176
14. Yates C, Sharp S, Jones J, et al. LHRH-conjugated lytic peptides directly target prostate cancer cells. Biochem Pharmacol 2011; 81: 104-110
15. Bono AV, Salvadore M, Celato N,. Gonadotropin-releasing hormone receptors in prostate tissue. Anal Quant Cytol Histol 2002; 24: 221-227
16. Kadar T, Ben-David M, Pontes JE, et al. Prolactin and luteinizing hormone-releasing hormone receptors in human benign prostatic hyperplasia and prostate cancer. Prostate 1988; 12: 299-307
17. Kadar T, Redding TW, Ben-David M, Schally AV,. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 1988; 85: 890-894
18. Lamharzi N, Halmos G, Armatis P, Schally AV,. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int J Oncol 1998; 12: 671-675
19. Straub B, Müller M, Krause H, et al. Increased incidence of luteinizing hormone-releasing hormone receptor gene messenger RNA expression in hormone-refractory human prostate cancers. Clin Cancer Res 2001; 7: 2340-2343
20. Straub B, Muller M, Krause H, Schrader M, Goessl C, Miller K,. Receptor gene messenger RNA expression in metastatic lesions of prostate cancer. J Urol 2002; 168: 1212-1214
21. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M,. The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999; 140: 5250-5256
22. Bahk JY, Hyun JS, Lee H, et al. Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 1998; 26: 259-264
23. Angelucci C, Lama G, Iacopino F, et al. GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine 2009; 36: 87-97
24. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M,. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992; 75: 207-212
25. Lamharzi N, Halmos G, Jungwirth A, Schally AV,. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 1998; 13: 429-435
26. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J,. The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990; 62: 96-99
27. Szabó J, Bartók K, Krenács T, Szepesváry Z, Szende B,. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas. Anticancer Res 2009; 29: 681-684
28. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M,. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994; 54: 4091-4095
29. Qayum A, Gullick WJ, Mellon K, et al. The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol 1990; 37: 899-902
30. Limonta P, Dondi D, Moretti RM, Fermo D, Garattini E, Motta M,. Expression of luteinizing hormone-releasing hormone mRNA in the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1993; 76: 797-800
31. Darby S, Stockley J, Khan MM, Robson CN, Leung HY, Gnanapragasam VJ,. Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. Endocr Relat Cancer 2007; 14: 613-624
32. Lau HL, Zhu XM, Leung PC, et al. Detection of mRNA expression of gonadotropin-releasing hormone and its receptor in normal and neoplastic rat prostates. Int J Oncol 2001; 19: 1193-1201
33. Azad N, Uddin S, La Paglia N, et al. Luteinizing hormone-releasing hormone (LHRH) in rat prostate: characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats. Endocrinology 1993; 133: 1252-1257
34. Dondi D, Festuccia C, Piccolella M, Bologna M, Motta M,. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system. Oncol Rep 2006; 15: 393-400
35. Motta M, Dondi D, Moretti RM, et al. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. J Steroid Biochem Mol Biol 1996; 56: 107-111
36. Castellón E, Clementi M, Hitschfeld C, et al. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 2006; 24: 261-268
37. Sánchez C, Clementi M, Benitez D, Contreras H, Huidobro C, Castellón E,. Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma. Prostate 2005; 65: 195-202
38. Ko YH, Ha YR, Kim JW, et al. Silencing of the GnRH type 1 receptor blocks the antiproliferative effect of the GnRH agonist, leuprolide, on the androgen-independent prostate cancer cell line DU145. J Int Med Res 2011; 39: 729-739
39. Ravenna L, Salvatori L, Morrone S, et al. Effects of triptorelin, a gonadotropin-releasing hormone agonist, on the human prostatic cell lines PC3 and LNCaP. J Androl 2000; 21: 549-557
40. Jungwirth A, Pinski J, Galvan G, et al. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer 1997; 33: 1141-1148
41. Jungwirth A, Galvan G, Pinski J, et al. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate 1997; 32: 164-172
42. Clementi M, Sánchez C, Benitez DA, et al. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate 2009; 69: 1025-1033
43. Angelucci C, Iacopino F, Lama G, et al. Apoptosis-related gene expression affected by a GnRH analogue without induction of programmed cell death in LNCaP cells. Anticancer Res 2004; 24: 2729-2738
44. Naor Z,. Signaling by G-protein-coupled receptor (GPCR): studies on the GnRH receptor. Front Neuroendocrinol 2009; 30: 10-29
45. Cheng CK, Leung PC,. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 2005; 26: 283-306
46. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY,. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 2005; 206: 205-213
47. Pinski J, Reile H, Halmos G, Groot K, Schally AV,. Inhibitory effects of analogs of luteinizing hormone-releasing hormone on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. Int J Cancer 1994; 59: 51-55
48. Plonowski A, Schally AV, Varga JL, et al. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 2000; 44: 172-180
49. Lamharzi N, Schally AV, Koppán M,. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Regul Pept 1998; 77: 185-192
50. Marelli MM, Moretti RM, Dondi D, Motta M, Limonta P,. Luteinizing hormone-releasing hormone agonists interfere with the mitogenic activity of the insulin-like growth factor system in androgen-independent prostate cancer cells. Endocrinology 1999; 140: 329-334
51. Montagnani Marelli M, Moretti RM, Mai S, Procacci P, Limonta P,. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 2007; 30: 261-271
52. Angelucci C, Lama G, Iacopino F, Sica G,. Leuprorelin acetate affects adhesion molecule expression in human prostate cancer cells. Int J Oncol 2011; 38: 1501-1509
53. Maudsley S, Davidson L, Pawson AJ, et al. Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5. Neuroendocrinology 2006; 84: 285-300
54. Sica G, Iacopino F, Settesoldi D, Zelano G,. Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells. Eur Urol 1999; 35 (Suppl. 1): 2-8
55. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
56. Beer TM, Garzotto M, Eilers KM, Lemmon D,. Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol 2003; 169: 1738-1741
57. Miller K, Rüssel C, Goble S, Persson BE,. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). Eur Urol Suppl 2010; 9: 76
58. Tao YX, Lei ZM, Woodworth SH, Rao CV,. Novel expression of luteinizing hormone/chorionic gonadotropin receptor gene in rat prostates. Mol Cell Endocrinol 1995; 111: R9-12
59. Reiter E, McNamara M, Closset J, Hennen G,. Expression and functionality of luteinizing hormone/chorionic gonadotropin receptor in the rat prostate. Endocrinology 1995; 136: 917-923
60. Tao YX, Bao S, Ackermann DM, Lei ZM, Rao CV,. Expression of luteinizing hormone/human chorionic gonadotropin receptor gene in benign prostatic hyperplasia and in prostate carcinoma in humans. Biol Reprod 1997; 56: 67-72
61. Tao YX, Lei ZM, Rao CV,. Seminal vesicles are novel sites of luteinizing hormone/human chorionic gonadotropin-receptor gene expression. J Androl 1998; 19: 343-347
62. Pinski J, Xiong S, Wang Q, Stanczyk F, Hawes D, Liu SV,. Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer. Prostate 2011; 71: 892-898
63. Dirnhofer S, Berger C, Hermann M, Steiner G, Madersbacher S, Berger P,. Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate. Prostate 1998; 35: 212-220
64. Radu A, Pichon C, Camparo P, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010; 363: 1621-1630
65. Hurkadli KS, Sheth AR, Garde SV, Doctor VM, Sheth NA,. Immunocytochemical localization of follicle stimulating hormone (FSH) in normal, benign and malignant prostates. Br J Cancer 1990; 61: 225-229
66. Garde SV, Sheth AR, Shah MG, Kulkarni SA,. Prostate-an extrapituitary source of follicle-stimulating hormone (FSH): occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents. Prostate 1991; 18: 271-287
67. Hurkadli KS, Shah MG, Pardanani DS, Sheth AR,. De novo biosynthesis of FSH like peptide by the human prostate. Life Sci 1990; 47: 391-400
68. Ben-Josef E, Yang SY, Ji TH, et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999; 161: 970-976
69. Mariani S, Salvatori L, Basciani S, et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006; 175: 2072-2077
70. Garnick MB, Campion M,. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 2000; 4: 275-277
71. Beer TM, Garzotto M, Eilers KM, Lemmon D, Wersinger EM,. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy. Urology 2004; 63: 342-347
72. Zaitsu M, Yamanoi M, Mikami K, et al. Surgical castration in hormone-refractory metastatic prostate cancer patients can be an alternative for medical castration. Adv Urol 2012; 2012: 979154
73. Lawrentschuk N, Fernandes K, Bell D, Barkin J, Fleshner N,. Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol 2011; 185: 848-854